| Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma (NCT07593040) | Vall d'Hebron Institute of Oncology | 2026-06-01 |
| Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) (NCT06630611) | Vall d'Hebron Institute of Oncology | 2025-01-15 |
| Combination Therapy for BRAF-V600E Metastatic CRCm (NCT06411600) | Vall d'Hebron Institute of Oncology | 2024-05-17 |
| Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer (NCT06385548) | Vall d'Hebron Institute of Oncology | 2024-05-01 |
| Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (NCT06377267) | Vall d'Hebron Institute of Oncology | 2024-02-06 |
| Phase I Prognostic Online (PIPO) Tool (NCT07593053) | Vall d'Hebron Institute of Oncology | 2023-02-02 |
| Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform (NCT05916755) | Vall d'Hebron Institute of Oncology | 2023-01-13 |
| A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 (NCT05385705) | Vall d'Hebron Institute of Oncology | 2022-05-11 |
| Single cEll pRofiling PErsistaNce To ImmuNothErapy (NCT06680739) | Vall d'Hebron Institute of Oncology | 2022-03-01 |
| Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors (NCT05141474) | Vall d'Hebron Institute of Oncology | 2021-10-28 |
| Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients (NCT05534178) | Vall d'Hebron Institute of Oncology | 2020-02-15 |
| Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (NCT03979131) | Vall d'Hebron Institute of Oncology | 2019-08-22 |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (NCT03767075) | Vall d'Hebron Institute of Oncology | 2018-12-10 |
| Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer (NCT05078151) | Vall d'Hebron Institute of Oncology | 2018-09-01 |
| Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (NCT03276013) | Vall d'Hebron Institute of Oncology | 2018-05-30 |
| Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer (NCT02982694) | Vall d'Hebron Institute of Oncology | 2017-11-24 |